85 related articles for article (PubMed ID: 377119)
1. [Anginin effect in cerebovascular disorders in the light of psychological studies].
Michalska I
Neurol Neurochir Pol; 1979; 13(2):141-6. PubMed ID: 377119
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic efficacy of pyridinolcarbamate (Anginin) in patients with combined cerebral and peripheral arteriosclerosis].
Majkowski J; Lysakowska-Sernicka K; Gajewska A; Bilińska-Nigot B; Ostrowski K; Semenicki K
Neurol Neurochir Pol; 1978; 12(4):387-96. PubMed ID: 714218
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of the effectiveness of anginin and stugeron treatment of cerebral arteriosclerosis].
Sobczyk W; Kruszewska J; Szymchel J
Neurol Neurochir Pol; 1980; 14(2):183-9. PubMed ID: 6993976
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of anginine in the treatment of cerebrovascular disorders (preliminary report)].
Majkowski J
Neurol Neurochir Pol; 1975; 9(3):381-8. PubMed ID: 1153068
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and rheoencephalographical evaluation of prodectin in the treatment of cerebral arteriosclerosis].
Wysocka-Bakowska MM
Neurol Neurochir Pol; 1981; 15(4):431-36. PubMed ID: 7035991
[TBL] [Abstract][Full Text] [Related]
6. [Pyridinolcarbamate (anginin) in the treatment of diabetic angiopathies].
Tirkina TN; Aleksandrova LM; Kliachko VR; Mazovetskiĭ AG
Ter Arkh; 1974; 46(1):107-10. PubMed ID: 4453966
[No Abstract] [Full Text] [Related]
7. [Pyridinolcarbamate treatment of ischemic heart disease].
Kuz'ko NV
Vrach Delo; 1976 Jan; (1):27-30. PubMed ID: 1246850
[No Abstract] [Full Text] [Related]
8. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
Pola P
Minerva Cardioangiol; 1975 Apr; 23(4):261-9. PubMed ID: 1095958
[No Abstract] [Full Text] [Related]
9. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
Pola P
J Pharm Sci; 1975 Jan; 64(1):261-9. PubMed ID: 1094102
[No Abstract] [Full Text] [Related]
10. The use of prodectin in the treatment of cerebral arteriosclerosis and its complications.
Abrányi I; Máté
Ther Hung; 1976; 24(1):20-3. PubMed ID: 790631
[No Abstract] [Full Text] [Related]
11. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
[No Abstract] [Full Text] [Related]
13. [Therapeutic results with combination of pyridinolcarbamate and clofibrate in atherosclerotic patients].
Valiensi M; Riboli E; Lombardi M
Minerva Cardioangiol; 1976 Feb; 24(2):148-54. PubMed ID: 1256654
[No Abstract] [Full Text] [Related]
14. [Atheroid and anginin in diabetic retinopathy].
Margolis MG; Zefirova GS; Shul'pina NB
Vestn Oftalmol; 1973; 1():38-41. PubMed ID: 4130225
[No Abstract] [Full Text] [Related]
15. [Effectiveness of pyridinolcarbamate in the overall treatment of infiltrative and cavernous-fibrous pulmonary tuberculosis].
Makinskiĭ AI; Safarov RN; Fondaminskaia LD; Semenova AS; Fedotova NN
Probl Tuberk; 1979 Jan; (1):26-30. PubMed ID: 368764
[No Abstract] [Full Text] [Related]
16. [Thermal test of reactive hyperemia: a propos of an objective study of pyridinol carbamate].
Lauliac M
Phlebologie; 1978; 31(2):119-29. PubMed ID: 693585
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory examinations with Prodectin.
Bédi J; Kosztovics A; Pálos LA
Ther Hung; 1976; 24(3):91-7. PubMed ID: 1013926
[No Abstract] [Full Text] [Related]
18. Attempts to delay progression in occlusive atherosclerosis.
Terry EN; Rouen LR; Clasuss RH; Katz MC; Redisch W
Ann N Y Acad Sci; 1976; 275():379-85. PubMed ID: 1070279
[No Abstract] [Full Text] [Related]
19. Modifications of platelet retention in patients treated with pyridinolcarbamate. A preliminary report.
Girolami A; Peruffo R; Emanueli A
Arzneimittelforschung; 1977; 27(6):1202. PubMed ID: 578441
[TBL] [Abstract][Full Text] [Related]
20. [Psychophysiological aspect of the therapeutic use of pyridinolcarbamate].
Sidorenko GI; Borisova GS; Sidorenko ER; Polonetskii LZ; Gelis LG
Kardiologiia; 1983 Mar; 23(3):66-71. PubMed ID: 6855067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
